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Embryonic stem cell (ESC) pluripotency is governed
by a gene regulatory network centered on the tran-
scription factors Oct4 and Nanog. To date, robust
self-renewing ESC states have only been obtained
through the chemical inhibition of signaling path-
ways or enforced transgene expression. Here, we
show that ESCs with reduced Oct4 expression re-
sulting from heterozygosity also exhibit a stabilized
pluripotent state. Despite having reduced Oct4
expression, Oct4+/ ESCs show increased genome-
wide binding of Oct4, particularly at pluripotency-
associated enhancers, homogeneous expression of
pluripotency transcription factors, enhanced self-
renewal efficiency, and delayed differentiation ki-
netics. Cells also exhibit increased Wnt expression,
enhanced leukemia inhibitory factor (LIF) sensitivity,
and reduced responsiveness to fibroblast growth
factor. Although they are able to maintain pluripo-
tency in the absence of bone morphogenetic protein,
removal of LIF destabilizes pluripotency. Our find-
ings suggest that cells with a reduced Oct4 concen-
tration range are maintained in a robust pluripotent
state and that the wild-type Oct4 concentration
range enables effective differentiation.
INTRODUCTION
Pluripotency is promoted and stabilized by a pluripotent-cell-
specific gene regulatory network (GRN) (Chambers and Tomlin-
son, 2009; Jaenisch and Young, 2008; Ng and Surani, 2011).
Central to this network are the transcription factors Oct4, Sox2,
and Nanog. ESCs fluctuate between states of high Nanog
expression, possessing high self-renewal efficiency and low
Nanog expression, exhibiting increased differentiation propen-
sity (Chambers et al., 2007). Notably, Nanog is also expressed
heterogeneously in the preimplantation embryo (Chazaud et al.,
2006; Dietrich andHiiragi, 2007; lowNanog expression facilitates
primitive endoderm differentiation, and high Nanog expression
maintains epiblast identity. The importance of the Nanog-low
state for proper embryonic development is underscored by the
finding that embryos expanded from the eight-cell stage in the
presence of drugs that inhibit MEK and fail to develop a primitive
endoderm (Nichols et al., 2009; Yamanaka et al., 2010);
conversely, the supplementation of embryos in culture with fibro-
blast growth factor (FGF) results in embryos in which epiblast
identity is lost in favor of primitive endoderm (Yamanaka et al.,
2010). In ESCs, MEK inhibition upregulates Nanog (Silva et al.,
2009). How FGF regulates Nanog is unknown, but the process
may involve the allelic regulation of Nanog through downstream
MEK targets (Miyanari and Torres-Padilla, 2012). In addition to
Nanog, other pluripotency factors, such as Esrrb (van den Berg
et al., 2008), Rex1 (Toyooka et al., 2008), Stella (Hayashi et al.,
2008), Klf4, and Tbx3 (Niwa et al., 2009), are expressed heteroge-
neously in ESCs. Although the mechanisms generating ESC het-
erogeneity have begun to be characterized (Fidalgo et al., 2012;
Navarro et al., 2012; Villasante et al., 2011), how populations of
ESCsexpressing homogeneously high levels of transcription fac-
tors arise in the presence of serum is not well understood.
Recently, ESCscultured in thepresenceofMEKandGSK inhib-
itors (Ying et al., 2008) have been reported to express a more ho-
mogenous level of pluripotency transcription factors (Wray et al.,
2010). However, the maintenance of this ‘‘ground state’’ requires
a continuous supply of MEK and GSK 3 inhibitors. Therefore, it is
of considerable interest to determinewhether a robust pluripotent
state can exist in the absence of such pharmacological inhibition.
Oct4 levels, generally considered tobe uniform in undifferentiated
ESCs, are critical not only in enabling self-renewal but also for the
outcome of differentiation (Niwa et al., 2000). However, these
prior studies focused either on the complete elimination or
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overexpression of Oct4. Here, we demonstrate that Oct4 levels in
ESCs cultured in serum occupy a broad unimodal peak; genetic
exclusionof thehighestOct4 expressersenables the robustprop-
agation of pluripotency with leukemia inhibitory factor (LIF) as the
sole requirement. In this condition, the binding of Oct4 to key reg-
ulatory nodes of the pluripotencyGRN is enhanced, and signaling
responses are tilted in favor of self-renewal.
RESULTS
Oct4+/– Cells Express Increased Nanog and Have a
Reduced Nanog-Negative Population
Global chromatin localization (Chen et al., 2008; Kim et al., 2008;
Loh et al., 2006;Marson et al., 2008) and transient expression as-
says (Kuroda et al., 2005; Rodda et al., 2005) suggest that Oct4
positively regulates Nanog gene expression. A clear prediction
from this is that cells that have reduced Oct4 levels should
have reduced Nanog levels. Therefore, it was with surprise that
we noted that multiple ESC lines in which homologous recombi-
nation had introduced a drug-resistance gene trap cassette to
the Oct4 locus, expressed elevated levels of Nanog protein and
messenger RNA (mRNA) when compared to Oct4+/+ ESCs (Fig-
ures 1A and 1B; see Table S1 [available online] for a list of cell
lines used in this study). Previously, Nanog has been demon-
strated to be expressed heterogeneously in undifferentiated
ESCs (Chambers et al., 2007; Hatano et al., 2005; Singh et al.,
2007). Therefore, this increase in Nanog protein could be due
to either a general increase in the level of Nanog per cell or an
alteration in the proportion of cells in the Nanog-negative
compartment. Immunofluorescence analysis showed that
Oct4+/ ESCs expressed Nanog more uniformly throughout the
colonies than Oct4+/+ ESCs and at levels comparable to those
present in Nanog-high nuclei in Oct4+/+ colonies (Figure 1C).
Although Oct4 protein has been reported to be expressed at
65% wild-type (WT) levels in populations of Oct4+/ ESCs by
immunoblot analysis (Niwa et al., 2000), the range of expression
in individual cells has not been addressed. Immunofluorescence
analysis (Figure 1D) shows that the range of Oct4 levels in indi-
vidual Oct4+/ cells strongly overlaps the distribution of Oct4
levels seen in WT cells. Not only do Oct4+/ ESC colonies have
a reduced number of cells that express high levels of Oct4 (Fig-
ure 1D), but, interestingly, cells that lack Oct4 are also missing
(Figure 1D), a point we return to below. Moreover, aggregation
ofOct4+/ ESCs with WT embryos showed that the Oct4 protein
levels inOct4+/ cells were within the range observed inWT inner
cell mass (ICM) cells (Figure 1F). Intracellular fluorescence-acti-
vated cell sorting (FACS) analysis in bulk ESC cultures showed
that the levels of both Oct4 and Nanog present in individual
Oct4+/ ESCs are within the normal range found in WT ESCs
(Figure 1E). In addition, although there is no effect of altering
the Nanog dosage upon the range of Oct4 expression levels,
as recently reported (Navarro et al., 2012), reducing Oct4 to
the level present in Oct4+/ ESCs shifts the level of Nanog to
the higher end of the range detected in WT ESCs. Altogether,
these results indicate that the increase in Nanog expression in
Oct4+/ cell lines is due to a reduction in the proportion of
Nanog-low and Nanog-negative cells.
To examine dynamic aspects of heterogeneous transcription
factor regulation, the previously described targeting vector
conferring Nanog-directed expression of green fluorescent pro-
tein (GFP) and puromycin resistance (Chambers et al., 2007) was
introduced into two different Oct4 mutant cell lines via homolo-
gous recombination (Figures S1A and S1B). The temporal
response to puromycin withdrawal confirmed that Oct4+/
ESCs retain homogenous GFP expression under conditions in
which typically heterogeneous GFP expression emerges in WT
cultures (Figure 1G).
Titrated Elevation of Oct4 Levels Restores the
Heterogeneous Expression of Nanog, Esrrb, and Klf4
The correlation between homogeneous Nanog expression and
Oct4 heterozygosity in independent cell lines suggests a caus-
ative role for the Oct4 protein level in the generation of Nanog
heterogeneity. To test this hypothesis, the effect of increasing
the Oct4 level was examined with ZHTc-Nanog:GFP cells (Fig-
ures S1A and S1 B and Table S1). In addition to the Nanog:GFP
reporter, these cells also contain a doxycycline-suppressible
Oct4 transgene. If homogeneous Nanog expression was
caused by reduced Oct4 levels, then raising the Oct4 level by
titrating down the doxycycline concentration should restore
Nanog heterogeneity. This was investigated by immunofluores-
cence (Figure 2A) and intracellular FACS (Figures 2B, S2A, and
S2B). No changes in Oct4 or Nanog were seen during the first
2 days; however, by day 3, increasing Oct4 expression was de-
tected at doxycycline concentrations of 0.3 ng/ml or less (Fig-
ure S2A). Interestingly, the level of Oct4 expression obtained
with 0.03 ng/ml doxycycline approached, but did not exceed,
the level observed in the Oct4+/+ control line E14Tg2a-
Nanog:GFP. Decreased Nanog expression also became detect-
able by day 3, and the population resolved into a bimodal
expression pattern by day 4 (Figures S2A and S2B). Importantly,
bimodal Nanog expression was achieved at the doxycycline
concentration (0.03 ng/ml) that elevated Oct4 toward WT levels
and did not require Oct4 overexpression (Figures S2A and 2A).
The restoration of Nanog heterogeneity was reflected by the
increased coefficient of variation of Nanog:GFP at doxycycline
concentrations of 0.1 ng/ml or less (Figure S2B). These results
indicate that the lack of Nanog-low and Oct4-low cells in
Oct4+/ cultures is not due to aberrant selection for cells with
an enhanced self-renewal propensity but is a consequence of
the Oct4 expression level; restoring the Oct4 level toward, but
not beyond, WT levels is sufficient to restore Nanog heteroge-
neity. Dynamically, the increase in Oct4 level results in
decreased Nanog expression in a subpopulation of cells, and,
subsequently, Oct4-low cells emerge from this Nanog-low pop-
ulation (Figure 2B).
The Nanog-low cells formed by doxycycline treatment of the
ZHTc-Nanog:GFP cells expressed high SSEA1+, suggesting
that they were undifferentiated (Figure S2C). Nevertheless, the
question remained as to whether Nanog-low cells induced in
ZHTc-Nanog:GFP cultures after Oct4 upregulation were already
committed to differentiate. Therefore, as schematized in Fig-
ure 2D, SSEA1+-GFP cells were sorted from ZHTc-Nanog:GFP
cells cultured in reduced doxycycline and replated in culture with
1 mg/ml doxycycline. By day 4, 35%of the sorted GFP cells had
reverted to a GFP+ state (Figure 2D). This not only indicates that
GFP cells can remain undifferentiated but also confirms the
crucial role of Oct4 in facilitating switching both from
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Figure 1. Oct4 +/– Cells Express an Elevated Level of NANOG and Lack a Nanog-Negative Population
(A) Immunoblot analysis of Oct4+/+ (E14Tg2a, CGR8, and ZIN40) and of Oct4+/ (OKO160 [Mountford et al., 1998] and ZHTc6 [cultured in 1 mg/ml doxycycline
[Niwa et al., 2000]) cell lines. See Table S1 for a detailed summary of all cell lines used in this study. ZHBTc4 (Oct4/) cells (Niwa et al., 2000), which express an
Oct4 transgene at heterozygous levels (when cultured without doxycycline) also showed increased Nanog. The parietal endoderm cell line D7A3/PE (Dani et al.,
1998) provides a negative control.
(B) Quantitative PCR (qPCR) analysis of Oct4 and Nanog mRNAs in Oct4+/+ (E14Tg2a and CGR8) and Oct4+/ (OKO160 and ZHTc6 [cultured in 1 mg/ml
doxycycline]) cells. Error bars represent SD; n = 3.
(C) Immunofluorescence analysis of wild-type (WT; E14Tg2a) and Oct4 mutant (OKO160, ZHTc6 [cultured in 1 mg/ml doxycycline], and ZHBTc4 [cultured without
doxycycline]) cells for Nanog (green) and Oct4 (red).
(D) Quantitative analysis of Oct4 protein levels in individual cells in colonies of Oct4+/+ (E14Tg2a, green) and Oct4+/ (OKO160, brown) cells.
(E) Intracellular FACS quantitation of Oct4 and Nanog protein levels in individual cells of Oct4+/+ (E14Tg2a, red) and Oct4+/ (OKO160, blue) cultures.
(F) Top, immunofluorescence analysis of blastocyst expression of Oct4 protein following the aggregation of GFP-markedOct4+/ ESCs withWTmorula. Bottom,
quantitation of immunofluorescence for Oct4 in the ICM for WT and GFP-marked Oct4+/ cells.
(G) FACS analysis for Nanog:GFP in Oct4 WT (Tg2a-Nanog:GFP) and Oct4 mutant cells (OKO-Nanog:GFP and ZHTc-Nanog:GFP [cultured in 1 mg/ml doxy-
cycline] derived from the parental lines OKO160 and ZHTc6, respectively; Oct4 genotypes are indicated) at the indicated times following release from puromycin
selection (day 0). The percentage of cells in Nanog-low, Nanog-middle, and Nanog-high populations are shown (red) with the coefficient of variation (CV) for
Nanog:GFP indicated.
See also Figure S1 and Tables S1 and S2.
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Nanog-high to Nanog-low states and also from Nanog-low to
Nanog-high states.
Immunofluorescence analysis showed that, similar to Nanog,
Esrrb and Klf4 were expressed relatively homogeneously in
Oct4+/ cultures (Figure S1C). Upon the restoration of Oct4 to-
ward WT levels, both Esrrb and Klf4 became heterogeneously
expressed (Figure 2C). Therefore, these findings identify Oct4
as a critical facilitator of the switch between heterogeneous
and homogeneous states of transcription factor expression in
ESCs.
ESCs Expressing Reduced Oct4 Levels Show Delayed
Differentiation
Oct4 has previously been shown to be necessary for ESC self-
renewal, given that the elimination of Oct4 results in trophecto-
dermal differentiation, whereas overexpression causes a pro-
portion of cells to differentiate into cells expressing endoderm
and mesoderm markers (Niwa et al., 2000). How Oct4 mediates
this differentiation remains unknown. A priori, it might be
expected that Oct4+/ cells would differentiate more rapidly.
However, the foregoing results showing that Oct4+/ cells have
a reduced proportion of Nanog-negative cells, along with the
model that differentiation occurs more effectively through
Nanog-low cells (Chambers et al., 2007), prompted an investiga-
tion of this point. Upon LIF withdrawal,Oct4+/ cell lines showed
delayed signs of morphological differentiation (Figure 3A),
delayed downregulation of the pluripotency markers Rex1
and FGF4, and reduced upregulation of the differentiation
markers Brachyury and Sox17 (Figure 3B) in comparison to
Oct4+/+ ESCs.
Figure 2. Titrated Elevation of Oct4 Levels Restores the Heterogeneous Expression of Nanog, Esrrb, and Klf4
(A) Immunofluorescence (Oct4, red) and fluorescence (Nanog:GFP, green) in ZHTc-Nanog:GFP cells treated with the indicated doxycycline concentrations for
6 days.
(B) Intracellular FACS analysis for Oct4 and Nanog:GFP at the indicated times of treatment with the indicated doxycycline dose.
(C) Immunofluorescence analysis at day 4 of doxycycline treatment of ZHTc-Nanog:GFP cells for Esrrb, Klf4, and Nanog:GFP.
(D) GFP-low ZHTc-Nanog:GFP cells remain undifferentiated and revert to a GFP-expressing state. Left, an experimental scheme; Oct4 expression was increased
inOct4+/ (ZHTc-Nanog:GFP) cells in order to induce Nanog heterogeneity, and cells were sorted into Nanog:GFP-high and Nanog:GFP-low populations. Right,
reanalysis of the sorted populations showed that they were >99% pure (day 0). Cells were replated in GMEMb-FCS-LIF-doxycycline (1,000 ng/ml) in order to
restore Oct4 protein to a Oct4+/ state and the emergence of the GFP-high population (indicated as a percentage) monitored daily.
See also Figure S2 and Table S1.
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Figure 3. ESCs Expressing Reduced Oct4 Levels Show Delayed Differentiation
(A) Morphology ofOct4+/+ (E14Tg2a and Oct4GiP [which carries an Oct4 promoter-driven GFP-ires-pac-pA cassette as an additive transgene]) (Ying et al., 2002)
and Oct4+/ (OKO160 and ZHTc6) cell lines at the indicated times after LIF withdrawal.
(B) qPCR analysis of mRNA expression in the indicated cell lines on the days shown after LIF withdrawal. Error bars represent SD; n = 3.
(C) qPCR analysis of mRNA expression in the indicated cell lines on the days shown after the initiation of monolayer neural differentiation. Error bars represent SD;
n = 3.
(D) Immunofluorescence for Nestin, Oct4, or bIII Tubulin at day 8 of neural differentiation. Cells were counterstained with DAPI.
(E) FACS analysis of Nanog:GFP and Pecam expression after the replating ofOct4+/+ (Tg2a-Nanog:GFP) andOct4+/ (OKO-Nanog:GFP) ESCs in activin-FGF for
the allowance of differentiation to an EpiSC state.
(F) qPCR analysis of mRNA expression in the indicated cell lines on the days shown after the replating of ESCs in activin-FGF2. Error bars represent SD; n = 3.
(G) Functional assessment of differentiation status. Following the outlined scheme (top), the differentiation status of ES-like colonies was assessed after 6 days
(Oct4+/+, E14Tg2a; Oct4+/, OKO160). Error bars represent SD; n = 4.
(H) JAK inhibitor blocks ESC self-renewal in the presence of LIF. ESCswere treated with JAK inhibitor for 6 days, replated at clonal density without JAK inhibitor in
GMEMb-FCS-LIF, cultured for an additional 6 days, and alkaline phosphatase-positive counted. Error bars represent SD; n = 3.
(I) EpiSC lines of the indicated genotypes (Oct4+/+, E14Tg2a; Oct4+/, OKO160) were passaged twice in the presence of the same JAK inhibitor concentration
used in (H), replated in GMEMb-FCS-LIF either in the presence or the absence of exogenous Esrrb, and assessed for colony-forming capacity after 6 days. Error
bars represent SD; n = 4.
See also Figures S3 and S4 and Tables S1 and S2.
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Figure 4. Pluripotency of Oct4+/– Cells Is Supported in the Absence of BMP
(A) Alkaline phosphatase staining of colonies formed by plating the indicated cell lines at clonal density and culturing for 7 days in GMEMb with 10% FCS and
100 U/ml LIF.
(B) Quantitation of colony types formed by cell lines shown in (A). Error bars represent SD; n = 3.
(C) Quantitation of colony types formed by platingOct4+/+ (E14Tg2a) andOct4+/ (OKO160) ESCs at clonal density in GMEMbwith 10%FCS and the indicated LIF
concentrations (U/ml) for 7 days. Error bars represent SD; n = 3.
(D) FACS analysis of Tg2a-Nanog:GFP andOKO-Nanog:GFP cells treated with the indicated LIF concentrations (U/ml) for 3 days. Before starting (day 0), cell lines
were selected for Nanog:GFP expression with puromycin.
(legend continued on next page)
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Neural differentiation (Ying et al., 2008) was also delayed in
Oct4+/ ESCs (Figures 3C and 3D). The persistence of large
numbers of Oct4-expressing cells inOct4+/ cultures (Figure 3D)
indicates that these cells were unable to undergo efficient neural
differentiation not because they were being diverted into non-
neural lineages but because they remained undifferentiated.
Next, the ability of Oct4+/ ESCs to differentiate into epiblast
stem cells (EpiSCs) was investigated by replating Oct4+/ and
Oct4+/+ ESCs in activin and FGF.Oct4+/ ESCs showed a slower
reduction in the expression of Nanog:GFP, Pecam (Figure 3E),
and ESC-specific transcripts and a delayed, diminished induc-
tion of EpiSC transcripts (Figure 3F). To functionally analyze
commitment, we replated cells into GMEMb-FCS-LIF after one
or two passages in N2B27-activin-FGF2. Cultures of Oct4+/
cells retain a greater ability to form alkaline phosphatase-
positive undifferentiated ESC colonies than Oct4+/+ cultures
(Figure 3G). These results indicate that Oct4+/ ESCs are
compromised in their ability to efficiently commit toward
differentiation and that this delay is in the initial exit from the
ESC state.
Nevertheless, EpiSC lines could be established from Oct4+/
ESCs by six passages in activin-FGF. Once established, cells
were passaged for an additional 2 weeks in the presence of a
JAK inhibitor in order to ensure the complete elimination of any
residual ESCs; effective JAK inhibition was confirmed with
ESCs (Figure 3H). Despite prior JAK inhibition, Oct4+/ EpiSCs
were able to form occasional colonies when replated in
GMEMb-FCS-LIF (Figure 3I), suggesting that, in the presence
of reduced Oct4 protein, the stringent separation between ESC
and EpiSC states is compromised. Oct4+/ EpiSCs also dis-
played a greater propensity to generate induced pluripotent
stem cells than WT cells, as shown by the increased colony
number formed after the expression of Esrrb (Festuccia et al.,
2012) and prior to replating in GMEMb-FCS-LIF (Figure 3I).
Restoration of Nanog Heterogeneity in Oct4+/– Cells
Rescues Retarded Differentiation
Our previous studies suggested that differentiation proceeds
efficiently after transient downregulation of Nanog (Chambers
et al., 2007). This predicts that the retarded differentiation ki-
netics of the Oct4+/ cells could be rescued by restoring a
Nanog-low compartment to the population. Therefore, we used
ZHTc-Nanog:GFP cells to vary the Oct4 level (as outlined in Fig-
ure S3A) and examined differentiation kinetics. Transient treat-
ment of ZHTc-Nanog:GFP cells for 4 days with the doxycycline
concentration shown in order to elevate Oct4 expression toward
WT levels (0.03 ng/ml; Figure S2A) produced a decrease in
Nanog mRNA (Figure S3B) and the heterogeneous expression
of Nanog:GFP (Figure S3A). Continued induction of the Oct4
transgene during the differentiation assays was prevented by
reapplying doxycycline at 1 mg/ml. After 8 days in the neural dif-
ferentiation protocol, cells in which heterogeneous Nanog
expression was initially imposed showed increased expression
of neural markers in comparison to cells maintained in 1 mg/ml
doxycycline (Figures S3C and S3D). The response of cells to
LIF withdrawal was also assessed. Cells in which heterogeneous
Nanog expression was initially induced showed a more differen-
tiated morphology (Figure S3E) and an enhanced expression of
differentiation markers (Figure S3F) in comparison to cells main-
tained in 1 mg/ml doxycycline. These results indicate that the
slower differentiation of Oct4+/ cells is attributable to a lack of
heterogeneous Nanog expression and that this can be rescued
by restoring the full range of Oct4 levels observed in WT ESCs.
Oct4-Induced Differentiation Is Blocked by Nanog
The above results suggest that differentiation induced by Oct4
elevation occurs via production of a differentiation-prone
Nanog-low population. If so, differentiation should be blocked
by enforced Nanog expression. This was tested with episomally
supertransfectable cells (Chambers et al., 2003) carrying a loxP-
flanked Nanog transgene (Nanog/T cells). In comparison to
control cells, which differentiated upon Oct4 transfection (Fig-
ure S4A), Nanog/T cells formedmorphologically undifferentiated
colonies (Figure S4A). To establish that this differentiation
blockade was due to transgenic Nanog expression, we deleted
the loxP-flanked Nanog ORF by Cre transfection. Cre-mediated
Nanog excision results in CAG-driven GFP expression. Although
most green colonies formed by Cre treatment of empty vector
transfectants had an undifferentiated morphology (Figures S4B
and S4C), themajority of green colonies derived fromOct4 trans-
fectants were completely differentiated (Figures S4B and S4C).
Therefore, Oct4 induces differentiation by the production of a
Nanog-low cell population.
Oct4+/– Cells Exhibit Enhanced Clonal Self-Renewal
Properties
In comparison to Oct4+/+ cell lines, clonal self-renewal assays
show that independent Oct4+/ ESC lines have an enhanced
ability to form uniformly undifferentiated colonies in response
to saturating LIF concentrations (Figures 4A and 4B). Further
clonal self-renewal assays showed that Oct4+/ ESCs have
30-fold greater sensitivity to LIF (Figure 4C). FACS analysis of
the effect of LIF concentration on Nanog expression showed
that, although Nanog was heterogeneous in WT cells even at
the highest LIF concentration, 10 U/ml LIF was sufficient tomain-
tain a unimodally high Nanog:GFP profile in Oct4+/ ESCs (Fig-
ure 4D). These results indicate that Oct4+/ ESCs show
enhanced responsiveness to LIF stimulation.
(E) Oct4+/+ (E14Tg2a) or Oct4+/ ESCs (OKO160-GFP) were plated at clonal density, cultured in N2B27 (with the indicated cytokines) for 7 days, and stained for
alkaline phosphatase.
(F) Oct4+/+ (AGFP7) or Oct4+/ (OKO160-GFP) ESCs were cultured in N2B27-LIF (100 U/ml) for 7 days at clonal density, replated for a further 7 days in the same
conditions, and stained for alkaline phosphatase.
(G)Oct4+/ ESCs (OKO160-GFP, which express a constitutive GFP transgene) cultured as described in (F) were injected into a host blastocyst and midgestation
embryos examined for the presence of ubiquitous GFP-expressing Oct4+/ cells by fluorescence microscopy.
(H) Oct4+/ ESCs (OKO-AGFP, which express a constitutive GFP transgene) were treated as described in (F) and (G). E11.5 genital ridges were analyzed by
immunofluorescence for Oct4 protein and GFP expression.
(I) Adult chimera from a blastocyst obtained as described in (G).
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In N2B27 supplemented with LIF and bone morphogenetic
protein (BMP), both Oct4+/+ and Oct4+/ cells formed self-re-
newing colonies, whereas, in N2B27 alone or in N2B27 supple-
mented with BMP alone, the formation of undifferentiated
colonies was severely impaired (Figure 4E). This was also true
for WT cells plated in the presence of LIF alone. In contrast,
Oct4+/ cells formed alkaline phosphatase-positive undifferenti-
ated colonies in LIF alone (Figure 4E).
Pluripotency of Oct4+/– Cells Is Supported in the
Absence of BMP/Serum/2i
To determine whether pluripotency could be sustained during
the clonal propagation of Oct4+/ cells in LIF alone, we obtained
derivative cells expressing GFP constitutively. These cells were
plated at clonal density, expanded, and replated at clonal den-
sity in defined medium in recombinant LIF without BMP. After
two passages, parental cells completely differentiated and could
not be sustained (Figure 4F). In contrast,Oct4+/ ESCs efficiently
formed uniformly alkaline phosphatase-positive undifferentiated
colonies (Figure 4F). Similar results were obtained when Oct4
was targeted in AGFP ESCs (Gilchrist et al., 2003). When
GFP+:Oct4+/ ESCs were injected into the blastocoel cavity of
a host C57Bl/6 host embryo, midgestation embryos were ob-
tained in which GFP+:Oct4+/ cells were widely distributed (Fig-
ure 4G) and detectable in the germline at E11.5 (Figure 4H).
When similarly injected embryos were allowed to develop to
term, adult coat color chimeras were obtained (Figure 4I). Alto-
gether, these data indicate that ESCs with reduced Oct4 levels
are released from BMP dependence.
Oct4 Action on Nanog
Oct4 binds to an octamer consensus site centered 176 bp up-
streamof theNanog transcription initiation site (Chambers, 2004;
Loh et al., 2006) that hasbeen shown topositively regulateNanog
in transient reporter assays (Kuroda et al., 2005; Rodda et al.,
2005). However, given that no data exist regarding the action of
Oct4 in the context of the endogenousNanog locus, the parsimo-
nious hypothesis that Oct4 suppresses Nanog via the 176 bp
octamer site was tested. Gene targeting introduced a mutant
version of the GFP-ires-pac-pA vector in which the octamer
site in the Nanog promoter was destroyed (Figure 5A), thus pro-
ducing mTg2a-Nanog:GFP ESCs (Figures S5A and S5B). In
puromycin, cells carrying theOct sitemutation show a slight shift
to lower GFP levels (Figure 5B). Removing puromycin from
mTg2a-Nanog:GFP cultures resulted in the increased emer-
gence of GFP-negative cells in comparison to Tg2a-Nanog:GFP
cells (Figures 5B and 5C). These effects, mirrored at the mRNA
level (Figure 5D), indicate that Oct4 regulates the endogenous
Nanog locus via the 176 bp site positively, not negatively.
Altered Signaling Responses in Oct4+/– ESCs
Thus far, the results suggest that Oct4+/ cells exist in a state of
enhanced stability that shares features of the naive ground state
(Wray et al., 2010; Ying et al., 2008). To examine the potential
connections between the Oct4+/ state and the ground state,
we induced Oct4 in ZHTc-Nanog:GFP cells in the presence of in-
hibitors of ERK and GSK3. The induction of Nanog heterogeneity
by Oct4 was blocked by treatment with inhibitors of FGFR, MEK,
or GSK3 (Figure 5E). These data suggest that elevating Oct4
from heterozygous levels induces heterogeneous Nanog
expression by modulating signaling responses.
Fgf4 signaling is implicated in the downregulation of Nanog in
ESCs (Hamazaki et al., 2006; Kunath et al., 2007) and in the in-
duction of heterogeneity in the ICM (Nichols et al., 2009; Yama-
naka et al., 2010). Consistent with this, adding recombinant FGF
to Tg2a-Nanog:GFP ESCs increased the proportion of
Nanog:GFP-low cells in the culture (Figure 5F). Given that Fgf4
is regulated by Oct4 (Ambrosetti et al., 1997; Yuan et al.,
1996), the lack of Nanog heterogeneity in Oct4+/ ESCs could
be due to reduced Fgf4 or altered Fgf receptor expression by
Oct4+/ ESCs. However, FGF4 transcripts were elevated in
Oct4+/ ESCs with no difference detectable in Fgfr2 transcript
level (Figure S5C). To further assess the dynamic effects of
FGF, we targeted GFP-ires-pac-pA to Nanog (Chambers et al.,
2007) in Fgf4/ ESCs (Figure S5D). FGF-Nanog:GFP ESCs ex-
press Nanog:GFP unimodally (Figure S5E), Nanog:GFP-low
cells being induced by FGF addition (Figure S5E). However, add-
ing FGF to parallel cultures of either OKO-Nanog:GFP or ZHTc-
Nanog:GFP ESCs did not affect Nanog:GFP, suggesting that the
lack of heterogeneity in Oct4+/ ESCs is due to an inability of
Oct4+/ ESCs to respond appropriately to FGF (Figure 5F). To
determine whether this lack of response was due to an inability
ofOct4+/ ESCs to elicit early events downstream of FGF recep-
tor, we examined the kinetics of ERK phosphorylation. When
ESCs were cultured in the absence of serum or cytokines
and stimulated with FGF, both Oct4+/+ and Oct4+/ ESCs
showed a comparable profile and duration of ERK phosphoryla-
tion (Figure 5G).
In contrast to FGF stimulation, LIF stimulation increased phos-
pho-ERK more strongly in Oct4+/ ESCs (Figure 5G). Phospho-
STAT3 was detected heterogeneously in Oct4+/+ ESCs cultured
in 100 U/ml LIF and predominantly in Nanog-expressing cells
(Figure 5H). In contrast, almost all Oct4+/ cells express phos-
pho-STAT3 (Figure 5H). Moreover, phospho-STAT3 became
heterogeneous when ZHTc-Nanog:GFP cells were shifted from
1,000 ng/ml to 0.03 ng/ml doxycycline (Figure 5I). Furthermore,
when parallel cultures ofOct4+/+ andOct4+/ ESCswere starved
and restimulated with LIF, phospho-STAT3 was induced to a far
higher level inOct4+/ ESCs (Figure 5J). These data suggest that
the difference in transcription factor heterogeneity in Oct4+/
ESCs may be due to enhanced LIF sensitivity mediated by
increased phospho-STAT3.
Previously, Wnt signaling has been reported to act synergisti-
cally with LIF in order to support ESC self-renewal (Hao et al.,
2006; Ogawa et al., 2006). Interestingly, Oct4+/ ESCs express
increasedWnt3a mRNA (Figure 6A) with Oct4 induction downre-
gulating Wnt3a (Figure 6A). Therefore, the potential of Wnt3a to
regulate Nanog heterogeneity was assessed by FACS. Wnt3a
blocked the emergence of a heterogeneous Nanog expression
profile from Tg2a-Nanog:GFP cultures in a dose-dependent
manner (Figure 6B). Wnt3a also prevented Oct4-induced Nanog
heterogeneity in Oct4+/ ESCs (Figure 6C). Moreover, the ability
of FGF to induce Nanog heterogeneity inOct4+/+ ESCswas high-
ly attenuated by Wnt3a (Figure 6D).
To further investigate molecular distinctions between Oct4+/+
and Oct4+/ ESCs, we performed microarray analysis on two
Oct4+/+ and two Oct4+/ ESC lines (Figures 6E and S6). This
identified 163 genes that differed consistently between the two
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Oct4+/+ and two Oct4+/ ESC lines (jlog2FCjR log2(1.25), false
discovery rate [FDR] % 0.1; see Experimental Procedures).
Functional enrichment analysis identified the biological pro-
cesses ‘‘Wnt receptor signaling pathway’’ (FDR = 0.0609) and
‘‘embryonic pattern specification’’ (FDR = 0.0397) as the only
gene ontology terms enriched in the candidate list. In addition
to Wnt3a, Wnt6 was increased in Oct4+/ ESCs, whereas the
Wnt antagonist Sfrp2 was decreased (Figure 6F). Furthermore,
several pluripotency transcription factors were elevated in
Oct4+/ ESCs (Figure 6G).
Oct4 and Nanog Occupancy in Oct4+/– ESCs
Next, we investigated the genome-wide binding profiles of Oct4
and Nanog in bothOct4+/ andOct4+/+ ESCs. For both Oct4 and
Figure 5. Signaling Influences in Oct4+/– ESCs
(A) TheNanog promoter sequence around the octamer site (red). Binding sites for Essrb (blue) and Sox2 (green) are also shown as is the sequence of the Oct4 site
mutation (red).
(B and C) Analysis of Tg2a-Nanog:GFP and a representative cell line containing a mutated Oct4 binding site (mTg2a-Nanog:GFP) after release from puromycin
treatment by FACS at days 6 and 18 (B) and fluorescent microscopy at day 18 (C).
(D) qPCR analysis of Oct4 and GFP transcripts in Tg2a-Nanog:GFP and mTg2a-Nanog:GFP cells at day 18 after puromycin removal. Error bars represent SD;
n = 3.
(E) FACS analysis of ZHTc-Nanog:GFP treated with or without doxycycline and in parallel with FGFR inhibitor (PD173074), MEK inhibitor (PD0325901), or GSK3
inhibitor (CHIR99021) for 6 days.
(F) FACS analysis of the indicated Nanog:GFP cell lines treated with or without FGF2 (10 ng/ml) for 6 days.
(G) Immunoblot analysis of phospho-ERK and total ERK in the indicated cell lysates prepared after overnight removal of FCS-LIF and stimulation with FGF2
(10 ng/ml) or LIF (100 U/ml) for the indicated time (min); PD indicates ESCs treated with PD0325901 for 4 hr.
(H) Immunofluorescence analysis for phospho-STAT3 and Nanog in the indicated cell lines.
(I) Immunofluorescence analysis for phospho-STAT3 and Nanog in ZHTc-Nanog:GFP cells after treatment with the indicated doxycycline concentrations.
(J) Immunoblot analysis of phospho-STAT3 in the indicated cell lysates prepared after overnight removal of LIF and stimulation with LIF (100 U/ml) for the
indicated time.
See also Figure S5 and Tables S1 and S2.
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Nanog, the majority of loci are shared between Oct4+/+ and
Oct4+/ ESCs (Figures S7A and S7B). However, striking differ-
ences in the binding intensity exist between Oct4+/+ and
Oct4+/ ESCs. At genes encoding pluripotency regulators (Esrrb,
Tbx3, Oct4, Klf5, and Wnt6), specific loci with increased Oct4
and/or Nanog occupancy were identified (Figure 7A, 7B, 7C,
S7C, S7D, and S7E). Such an increase was not found at other
loci (e.g., Figure 7D). Next, we asked whether genes with
increasedOct4 occupancy are associatedwith gene expression.
Genes near Oct4-binding events that are enhanced in Oct4+/
ESCs are significantly enriched in the set of genes with higher
expression in Oct4+/ ESCs (p = 1.7 3 1037; Figure 7E),
whereas Oct4-binding events reduced in Oct4+/ ESCs occur
near genes with higher expression in Oct4+/+ ESCs (p = 1.2 3
108, Figure S7F). This change in gene expression is reflected
in epigenetic differences. Genes where the promoter shows
reduced levels of the repressive histone modification
H3K27me3 in Oct4+/ ESCs in comparison to Oct4+/+ ESCs
show higher expression in Oct4+/ ESCs (Figure 7F; p = 1.9 3
1019). Altogether, this indicates that qualitative differences of
Figure 6. Wnt and Transcription Factor Distinctions between Oct4+/+ and Oct4+/– ESCs
(A) qPCR analysis of E14Tg2a and OKO160 ESCs for the indicated transcripts (left) and ZHTc-Nanog:GFP ESCs treated with the indicated doxycycline dose for
4 days (right). Error bars represent SD; n = 3.
(B) FACS analysis of Nanog:GFP expression in Tg2a-Nanog:GFP cells treated with the indicated Wnt3a concentrations for 3 days.
(C) FACS analysis of Nanog:GFP expression in ZHTc-Nanog:GFP cells treated without doxycycline in the presence or absence of Wnt3a (80 ng/ml).
(D) FACS analysis of Nanog:GFP expression in FGF-Nanog:GFP cells treated with FGF2 in the presence or absence of Wnt3a (80 ng/ml).
(E) A comparison of the mean-quantile-normalized gene-expression levels in Oct4+/+ (E14Tg2a and OctGIP) and Oct4+/ (OKO160 and ZHTc6) ESCs. Genes
differentially and consistently overexpressing (‘‘induced’’ by Oct4) or underexpressing (‘‘repressed’’ by Oct4) in Oct4+/+ versus Oct4+/ (jlog2FCjR log2(1.25),
FDR% 0.1; see Experimental Procedures) are highlighted in blue and orange, respectively. Boundaries for a 1.253 fold change are shown in red.
(F) Average quantile-normalized expression intensities for Wnt signaling and pluripotency-related (G) genes. Error bars represent SEM.
See also Figure S6 and Tables S1, S2, and S3.
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Oct4 occupancy along with epigenetic differences are involved
in regulating the robustness of the pluripotent state via effects
on the pluripotency GRN.
Surprisingly, even though Oct4 protein is reduced in Oct4+/
ESCs, the binding sites with the strongest difference between
Oct4+/+ and Oct4+/ ESCs show increased occupancy in
Oct4+/ ESCs. These Oct4+/-specific Oct4 binding sites occur
largely at genomic loci associated with p300 and H3K4me1,
but not H3K4me3 (Figures 7G, 7H, and 7I). p300 and
H3K4me1 are classical marks for enhancer regulatory sites,
whereas H3K4me3 is highly abundant at proximal promoters.
In addition, the sites that show enhanced Oct4 occupancy in
the Oct4+/ ESCs are generally further from the transcription
start sites (Figure S7G). Moreover, loci showing enhanced oc-
cupancy by Oct4 also exhibit enhanced co-occupancy by
Nanog (Figure S7H).
These data point toward an increase in Oct4 occupancy at
enhancer regulatory regions in the Oct4+/ ESCs. The proximal
and distal enhancers ofOct4 (Figure 7C) are of particular interest.
The distal enhancer, which is associated with preimplantation
embryos and ESCs (Yeom et al., 1996; Han et al., 2010), shows
increased binding of Oct4 andNanog inOct4+/ ESCs. The prox-
imal enhancer, which is associated with postimplantation
epiblast and EpiSCs (Yeom et al., 1996), shows decreased bind-
ing of Nanog. Thus, reduced Oct4 protein levels inOct4+/ ESCs
appear to induce a shift in Oct4 binding preferences toward a
higher occupancy of key regulatory elements, thereby strength-
ening the regulatory network that maintains robust pluripotency.
Figure 7. Genome-Wide Analysis for Oct4 and Nanog Occupancy in Oct4+/– ESCs
(A–D) Chromatin immunoprecipitation sequencing profiles of Oct4 and Nanog for Esrrb (A), Tbx3 (B), Oct4 (C), and Slc7a10 (D) gene loci in Oct4+/+ ESCs and
Oct4+/ ESCs . Read counts are normalized by the number of uniquely mapped reads.
(E) Genes with increasedOct4 binding within 50 kb of the transcription start site (TSS) inOct4+/ ESCs are enriched in the gene set showing increased expression
in Oct4+/ ESCs; significance was estimated by Fisher’s exact test.
(F) Genes with reduced levels of H3K27me3 in Oct4+/ ESCs are enriched in the gene set showing increased expression in Oct4+/ ESCs; significance was
estimated by Fisher’s exact test.
(G–I) Average read count for p300 (G), H3K4me1 (H), and H3K4me3 (I) at Oct4 binding sites shared between Oct4+/+ and Oct4+/ ESCs (black) or showing
increased Oct4 occupancy in Oct4+/ ESCs (red).
(J) A model of the pluripotency GRN. ESCs express a range of Oct4 concentrations (red circles), only the lower of which are present inOct4+/ ESCs (green box).
In this lower state, Oct4 binds strongly to key regulatory genes, encoding heterogeneously expressed transcription factors and Wnt signaling components. The
increased Wnt signaling results in enhanced phospho-STAT3 levels in response to LIF, further reinforcing the expression of heterogeneously expressed plu-
ripotency transcription factors. This produces upward pressure on the Oct4 gene, driving cells into the high Oct4 concentration range (yellow arrow 1). At these
high Oct4 concentrations (white box), the Wnt system is not activated and Oct4 binding to transcription factor loci is weakened. Exit of cells from this state can
result either from the residual GRN activity, causing downward fluctuation in the Oct4 expression (yellow arrow 2) or from the cell experiencing an effective
commitment signal (yellow arrow 3).
See also Figure S7 and Tables S1, S3, and S4.
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DISCUSSION
Although the heterogeneous expression of pluripotency tran-
scription factors has the capacity to generate multiple outcomes
from a single functionally defined cell type (Canham et al., 2010;
Chambers et al., 2007; Glauche et al., 2010; Kalmar et al., 2009;
Singh et al., 2007), the factors controlling heterogeneity are only
beginning to be elucidated. Nanog autorepression has recently
been demonstrated (Fidalgo et al., 2012; Navarro et al., 2012)
with this contributing to Nanog heterogeneity (Navarro et al.,
2012). In addition, Satb1, Satb2, and Ezh2 have been reported
to influence Nanog heterogeneity (Savarese et al., 2009; Villa-
sante et al., 2011). In this study, we identify an origin for
transcription factor heterogeneity within the circuitry of the plu-
ripotency GRN. Multiple Oct4+/ ESC lines have a unimodal
high Nanog expression profile and lack Nanog-low undifferenti-
ated cells. Heterogeneity is caused by a higher range of Oct4
levels present in WT ESC cultures because increasing the Oct4
concentration range toward the WT distribution switches Nanog
to a bimodal heterogeneous profile.
The fact that Oct4+/ cultures not only lack cells expressing
the highest Oct4 concentrations present in Oct4+/+ cultures but
are also essentially devoid of the differentiated Oct4-negative
cells that are readily detectable in WT cultures is of no small in-
terest here. These findings have two important implications.
First, the full range of Oct4 concentrations present in the
Oct4+/ population is within the distribution of expression levels
observed both in WT ESC cultures and in the WT ICM, indicating
that the Oct4 protein levels in Oct4+/ cells are physiologically
relevant. Second, the appearance of differentiated Oct4-nega-
tive cells in ESC cultures is part of the normal network configura-
tion assembled by WT Oct4 levels and does not require exces-
sive Oct4 expression.
The more homogeneous expression of transcription factors
present inOct4+/ ESCs results in delayed differentiation in com-
parison toWT ESCs. Importantly, restoring Nanog heterogeneity
in Oct4+/ ESCs by transiently increasing the Oct4 level
re-established normal differentiation. Furthermore, enforced
expression of Nanog prevents differentiation induced by Oct4
elevation. Altogether these findings offer an explanation for the
original observation that an increase in Oct4 can cause differen-
tiation (Niwa et al., 2000). Rather than being a consequence of
Oct4 action at elevated concentrations, our results show that
Oct4 acts at physiological levels to provide a population of
Nanog-low cells responsive to differentiation cues.
Our results establish unequivocally that a state of homoge-
neous transcription factor expression and robust self-renewal
can exist without the need for pharmacological signaling
pathway inhibition (Ying et al., 2008). The reasons for this are
manifold. First, Oct4+/ ESCs exhibit an increased sensitivity to
LIF. This can be seen by enhanced STAT3 phosphorylation,
enhanced colony-forming capacity at low LIF concentrations,
and enhanced maintenance of unimodally high Nanog:GFP
expression at low LIF concentrations. This increased sensitivity
to LIF is accompanied by a resistance to the induction of Nanog
heterogeneity and differentiation in response to FGF. Interest-
ingly, Oct4+/ ESCs respond to FGF by increasing ERK phos-
phorylation, suggesting that the lack of a full response to FGF
in these cells is due to either the interception and elimination of
effective signaling downstream of ERK or the dominance of an
opposing signal. FGF4 mRNA expression is elevated in
Oct4+/ cells, which may reflect dysregulation of the FGF
signaling system in these cells. The combined inhibition of ERK
and GSK3b has been spectacularly successful for the derivation
of ESCs from recalcitrant strains of mice (Ying et al., 2008) and
from other species (Buehr et al., 2008; Li et al., 2008). Perhaps
the inability to derive ESCs from the majority of non-129 mouse
strains is due to the expression level of Oct4 being beyond the
range that can be stabilized in culture by LIF.
Oct4+/ cells also exhibit elevated expression of Wnt6 and
Wnt3a and decreased expression of Sfrp2, which is indicative
of a shift in the Wnt signaling system. Wnt3a has previously
been reported to act in synergy with LIF on ESCs (Ogawa et al.,
2006); although, without LIF, Wnt3a cannot maintain an
undifferentiated ESC state. Indeed, in the presence of Wnt3a,
LIF concentrations as low as 6 U/ml can support undifferentiated
colony formation by WT ESCs (Ogawa et al., 2006). Here, we
show that, at this LIF concentration, the majority of Oct4+/
ESCscolonies are completely undifferentiated. Supplementation
of ESC cultures with Wnt3a has also been reported to block the
transition from ESCs to EpiSCs but, again, only when LIF is also
added (ten Berge et al., 2011). Not only dowe observe a retarded
transition to EpiSCs by Oct4+/ ESCs, but we also find that
Oct4+/ ESCs can be clonally propagated in LIF-N2B27 in the
absence of either BMP or signaling inhibitors (Ying et al., 2008).
Although the differentiation ofOct4+/ ESCs to an EpiSC state
is delayed, Oct4+/ EpiSCs can be established. An interesting
property of Oct4+/ EpiSCs is the capacity to form undifferenti-
ated ESC-like colonies when replated in LIF-fetal calf serum
(FCS). It has been reported previously that EpiSCs can revert
to an ESC-like state after culture on feeder cells (Bao et al.,
2009). However, this reversion is slow, requiring >20 days. In
contrast, Oct4+/ EpiSCs form ESC-like colonies in the absence
of feeder cells within 6 days. This suggests that the distinction
between the ESC and EpiSC pluripotent states is less clear-cut
in cell populations expressing a reduced Oct4 concentration
range. This may indicate that the higher Oct4 concentrations
present in WT ESCs are important in imparting unidirectionality
upon developmental progression.
It is of interest that Oct4+/ ESCs show increased STAT3
phosphorylation in response to LIF. This may be related to the
altered expression of Wnt signaling ligands in Oct4+/ ESCs,
given that evidence has been presented that Wnt3a may in-
crease STAT3 expression (Hao et al., 2006). Although Oct4 upre-
gulation and a decrease in LIF concentration result in a similar
differentiation phenotype (Niwa et al., 2000), no connection has
previously been made between Oct4 and STAT3 signaling.
Here, we show that the degree of STAT3 phosphorylation varies
with levels of Oct4 and surprisingly, in Oct4+/ ESCs, phosphor-
ylated STAT3 can be detected in almost every cell. This con-
trasts with WT ESCs and suggests that insufficient or attenuated
STAT3 signaling may contribute to ESC heterogeneity. These re-
sults suggest thatOct4+/ ESCs are primed to respond to LIF via
enhanced STAT3 phosphorylation. The possibility that enhanced
STAT3 signaling may have a dominant effect over signals antag-
onistic to ESC self-renewal such as ERK has been suggested
(van Oosten et al., 2012). Therefore, our findings that Oct4+/
EpiSCs have a higher reprogramming efficiency thanWT EpiSCs
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may, at least in part, be due to the enhanced phosphorylation of
STAT3 in Oct4+/ cells.
LIF has been reported to be upstream of transcription factor
expression (Niwa et al., 2009). Therefore, we propose that
enhanced STAT3 phosphorylation leads to the more homoge-
nous expression of pluripotency factors such as Nanog, Klf4,
and Esrrb. Under such conditions, the profile of Oct4 binding
shifts to sites more distal to transcription start sites. A prime
example is the Oct4 gene. The distal Oct4 enhancer, which is
more functional than the proximal enhancer in ESCs and the
ICM than in EpiSCs and the postimplantation epiblast (Han
et al., 2010; Yeom et al., 1996), is more fully occupied by
Oct4 in Oct4+/ ESCs where the Oct4 concentration is
reduced. These observations suggest that the robust network
configuration of Oct4+/ ESCs reflects an early developmental
state.
Theoretical models have been proposed to explain heteroge-
neous Nanog expression (Glauche et al., 2010; Kalmar et al.,
2009). Both involve negative feedback onNanog, and onemodel
proposes Oct4 as a negative regulator of Nanog (Kalmar et al.,
2009). Our work establishes the veracity of this conjecture but re-
veals that a state of nondynamic unimodal Nanog expression ex-
ists at diminished Oct4 levels.
Our findings can be incorporated into a model in which Oct4
plays two diverse roles (Figure 7J). At the lower range of Oct4
concentrations found in WT ESCs and typified by Oct4+/
ESCs, Oct4 binds strongly to chromatin at key regulatory ele-
ments, directing the homogenous expression of pluripotency
transcription factors and the expression of Wnt signaling
components. This increased Wnt signaling activity enhances
cell sensitivity to LIF (Hao et al., 2006; Ogawa et al., 2006),
further re-enforcing the pluripotency GRN (Niwa et al., 2009)
and making cells more refractory to differentiation signals
such as FGF. This state can be maintained in Oct4+/ ESCs
because the upward pressure of the re-enforced pluripotency
transcription factors on the Oct4 loci cannot enforce Oct4 pro-
tein elevation because of the deletion of one of the Oct4 alleles.
However, in Oct4+/+ cells, this movement into the higher Oct4
concentration range can occur. Then, the Wnt signaling system
is no longer stimulated by Oct4, and the pluripotency transcrip-
tion factors are expressed at a lower level. ESCs may exit this
Oct4-high state by diminishing Oct4 expression as a con-
sequence of the weakened transcription factor network
strength, thereby reverting to an Oct4-low concentration range
or by responding to a commitment signal (e.g., FGF) and
differentiating.
A priori, one might have expected the pluripotency GRN to
have been optimally configured to support robust ESC self-
renewal. In this respect, the demonstration that such robust
ESC self-renewal is anchored through a network configuration
orchestrated by reduced Oct4 concentrations is highly unex-
pected. This indicates that the control of pluripotent cell identity
is naturally arranged in ESCs and ICM cells to provide heteroge-
neity. Consequently, stem cell self-renewal and rapid respon-
siveness to differentiation cues can simultaneously reside in a
single stem cell population in which individual cells experience
the same environmental stimuli. When one considers the situa-
tion in the embryo, it is perhaps less surprising that the network
is not optimized for extended self-renewal, given that progres-
sion beyond the pluripotent state is required for orderly
development. It will be of considerable interest to determine
whether similar strategies are used in other stem cell systems




ESCs were cultured in GMEMbwith 10% FCS and 100 U/ml LIF on gelatinized
tissue culture flasks at a density of 2.5–10 3 104/cm2 (Smith, 1991). Differen-
tiationwas induced by LIFwithdrawal (Smith, 1991) with a neural differentiation
protocol (Ying et al., 2008) or into EpiSCs, as described previously (Osorno
et al., 2012). Recombinant Wnt3a (R&D Systems) and recombinant Fgf2
(R&D) were used as indicated. JAK inhibitor I (Calbiochem) was used at
0.6 mM and PD0325901 (Axon Medchem) and Chiron 99021 (Axon) were
used as described previously (Ying et al., 2008). Introduction of the
Nanog:GFP reporter by homologous recombination was performed and veri-
fied as described previously (Chambers et al., 2007).
Colony-Forming Assay
The colony-forming assay was performed by seeding 600 cells in a well of a
six-well plate (60 cells/cm2). Cells were plated in GMEMb-FCS with or without
LIF or in N2B27 (Ying et al., 2008) supplemented with recombinant LIF (Sigma-
Aldrich) and/or recombinant BMP4 (R&D) as indicated and cultured in a 37C,
7% CO2 incubator. After 7 days, cell staining was performed with an Alkaline
Phosphatase Detection Kit (Sigma-Aldrich).
Immunofluorescence Quantifications
For ESC quantifications, cells were segmented on the basis of DAPI with the
nuclei detection algorithm of PerkinElmer’s Acapella Image Analysis Suite.
For each nucleus, mean fluorescence for Oct4 and Nanog were computed.
For embryo quantification, the fluorescence signal in each nucleus of whole-
mount immunostained blastocysts were quantified with an automated pipeline
as described previously (Osorno et al., 2012), except that preprocessed DAPI-
stained nuclei of RGB stack images were segmented with the FARSIGHT
Toolkit (Al-Kofahi et al. 2010) (http://www.farsight-toolkit.org/) and incorrectly
segmented nuclei were manually rectified with the FARSIGHT Nucleus Editor.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2013.04.023.
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